v3.25.2

Condensed Consolidated Balance Sheets - USD ($)	Apr. 30, 2025	Oct. 31, 2024
Current assets
Cash and cash equivalents	$ 2,093,075	$ 6,767,356
Marketable securities	8,313,189	5,978,104
Accounts receivable	2,684,052	2,510,909
Prepaids and other assets	327,089	442,384
Total current assets	13,417,405	15,698,753
Property and equipment, net	145,234	169,281
Operating lease right-of-use	115,259	198,597
Other assets	225,643	225,599
Total assets	13,903,541	16,292,230
Current liabilities
Current operating lease liabilities	113,044	165,201
Accounts payable and accrued expenses	937,907	1,127,649
Current portion of US Tax Reform Transition Tax and income taxes payable	729,282	594,316
Total current liabilities	1,780,233	1,887,166
US Tax Reform Transition Tax payable	0	660,903
Long-term operating lease liabilities	0	28,834
Total liabilities	1,780,233	2,576,903
Stockholders' equity
Preferred Stock, $0.0001 par value; authorized 10,000,000 shares; none outstanding	0	0
Common Stock, $0.0001 par value; authorized 50,000,000 shares; 23,519,672 and 23,512,880 shares issued, and 22,928,642 and 22,958,143 shares outstanding at April 30, 2025 and October 31, 2024, respectively	2,352	2,352
Additional paid-in capital	1,665,149	1,644,468
Retained earnings	10,737,941	12,353,970
Accumulated other comprehensive income	282,946	262,380
Treasury stock, at cost; 591,030 and 561,529 common shares held at April 30, 2025 and October 31, 2024, respectively	(565,080)	(547,843)
Total stockholders' equity	12,123,308	13,715,327
Total liabilities and stockholders' equity	$ 13,903,541	$ 16,292,230

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Pharma-Bio Serv, Inc. 10-Q